Barclays reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report report published on Friday.
Other analysts have also recently issued reports about the stock. Peel Hunt raised shares of Hikma Pharmaceuticals to an add rating and lifted their target price for the stock from GBX 1,160 ($15.16) to GBX 1,950 ($25.48) in a research note on Thursday, August 16th. Citigroup lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the stock a buy rating in a research note on Monday, August 20th. Jefferies Financial Group raised shares of Hikma Pharmaceuticals to a buy rating and lifted their target price for the stock from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a research note on Tuesday, November 27th. Finally, Numis Securities reaffirmed a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of GBX 1,815.71 ($23.73).
HIK stock opened at GBX 1,704.50 ($22.27) on Friday. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.64) and a one year high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Story: What are Institutional Investors?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.